Literature DB >> 24300133

Alterations in cytochrome P450-derived arachidonic acid metabolism during pressure overload-induced cardiac hypertrophy.

Ahmed A El-Sherbeni1, Ayman O S El-Kadi2.   

Abstract

Cardiac hypertrophy is a major risk factor for many serious heart diseases. Recent data demonstrated the role of cytochrome P450 (CYP)-derived arachidonic acid (AA) metabolites in cardiovascular pathophysiology. In the current study our aim was to determine the aberrations in CYP-mediated AA metabolism in the heart during cardiac hypertrophy. Pressure overload cardiac hypertrophy was induced in Sprague Dawley rats using the descending aortic constriction procedure. Five weeks post-surgery, the cardiac levels of AA metabolites were determined in hypertrophied and normal hearts. In addition, the formation rate of AA metabolites, as well as, CYP expression in cardiac microsomal fraction was also determined. AA metabolites were measured by liquid chromatography-electrospray ionization-mass spectroscopy, whereas, the expression of CYPs was determined by Western blot analysis. Non-parametric analysis was performed to examine the association between metabolites formation and CYP expressions. Our results showed that 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs), and 5-, 12-, 15-, and 20-hydroxyeicosatetraenoic acids (HETEs) levels were increased, whereas, 19-HETE formation was decreased in hypertrophied hearts. The increase in EETs was linked to CYP2B2. On the other hand, CYP1B1 and CYP2J3 were involved in mid-chain HETE metabolism, whereas, CYP4A2/3 inhibition was involved in the decrease in 19-HETE formation in hypertrophied hearts. In conclusion, CYP1B1 played cardiotoxic role, whereas, CYP2B2, CYP2J3 and CYP4A2/3 played cardioprotective roles during pressure overload-induced cardiac hypertrophy. These CYP can be valid targets for the development of drugs to treat and prevent cardiac hypertrophy and heart failure.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Arachidonic acid metabolism; Cardiac hypertrophy; Cytochrome P450; Eicosanoids; Heart failure

Mesh:

Substances:

Year:  2013        PMID: 24300133     DOI: 10.1016/j.bcp.2013.11.015

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

1.  The role of cytochrome P450 1B1 and its associated mid-chain hydroxyeicosatetraenoic acid metabolites in the development of cardiac hypertrophy induced by isoproterenol.

Authors:  Zaid H Maayah; Hassan N Althurwi; Ahmed A El-Sherbeni; Ghada Abdelhamid; Arno G Siraki; Ayman O S El-Kadi
Journal:  Mol Cell Biochem       Date:  2017-03-01       Impact factor: 3.396

Review 2.  Unraveling the Role of 12- and 20- HETE in Cardiac Pathophysiology: G-Protein-Coupled Receptors, Pharmacological Inhibitors, and Transgenic Approaches.

Authors:  Jonathan V Pascale; Pamela A Lucchesi; Victor Garcia
Journal:  J Cardiovasc Pharmacol       Date:  2021-06-01       Impact factor: 3.271

Review 3.  Role of Oxidative Stress in Thyroid Hormone-Induced Cardiomyocyte Hypertrophy and Associated Cardiac Dysfunction: An Undisclosed Story.

Authors:  Mohammad T Elnakish; Amany A E Ahmed; Peter J Mohler; Paul M L Janssen
Journal:  Oxid Med Cell Longev       Date:  2015-06-04       Impact factor: 6.543

4.  The Mitochondria-Targeted Antioxidant SkQ1 Downregulates Aryl Hydrocarbon Receptor-Dependent Genes in the Retina of OXYS Rats with AMD-Like Retinopathy.

Authors:  M L Perepechaeva; A Yu Grishanova; E A Rudnitskaya; N G Kolosova
Journal:  J Ophthalmol       Date:  2014-07-14       Impact factor: 1.909

Review 5.  The Physiopathology of Cardiorenal Syndrome: A Review of the Potential Contributions of Inflammation.

Authors:  John G Kingma; Denys Simard; Jacques R Rouleau; Benoit Drolet; Chantale Simard
Journal:  J Cardiovasc Dev Dis       Date:  2017-11-29

6.  CYP1B1 as a therapeutic target in cardio-oncology.

Authors:  Alexa N Carrera; Marianne K O Grant; Beshay N Zordoky
Journal:  Clin Sci (Lond)       Date:  2020-11-13       Impact factor: 6.124

7.  Ophiopogonin D Increases SERCA2a Interaction with Phospholamban by Promoting CYP2J3 Upregulation.

Authors:  Jia Wang; Wenting You; Ningning Wang; Wei Zhou; Yunxuan Ge; Zengchun Ma; Hongling Tan; Yuguang Wang; Yue Gao
Journal:  Oxid Med Cell Longev       Date:  2020-12-31       Impact factor: 6.543

8.  Site-directed deuteration of dronedarone preserves cytochrome P4502J2 activity and mitigates its cardiac adverse effects in canine arrhythmic hearts.

Authors:  Aneesh V Karkhanis; Gopalakrishnan Venkatesan; Ryuichi Kambayashi; Jacqueline Wen Hui Leow; Marcus Qingrui Han; Hiroko Izumi-Nakaseko; Ai Goto; Jeremy Kah Sheng Pang; Boon Seng Soh; Pipin Kojodjojo; Atsushi Sugiyama; Eric Chun Yong Chan
Journal:  Acta Pharm Sin B       Date:  2022-03-16       Impact factor: 14.903

9.  Resveratrol attenuates angiotensin II-induced cellular hypertrophy through the inhibition of CYP1B1 and the cardiotoxic mid-chain HETE metabolites.

Authors:  Sherif M Shoieb; Ayman O S El-Kadi
Journal:  Mol Cell Biochem       Date:  2020-06-12       Impact factor: 3.396

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.